Drugs / Recombinant live attenuated trivalent dengue vaccine
Recombinant live attenuated trivalent dengue vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02433652 | Sep 2015 → Nov 2016 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant live attenuated trivalent dengue vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02433652 ↗ |
| Modality | Vaccine | “trivalent live attenuated dengue admixture vaccine” NCT02433652 ↗ |